What the FDA's 503A Category 2 List Actually Means for Peptide Access
The single most consequential regulatory action in the peptide space was not a ban — it was a bulk-substance classification that quietly removed BPC-157, CJC-1295, ipamorelin, and thymosin alpha-1 from lawful US compounding.
Under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy may compound with a bulk drug substance only if that substance is the subject of an applicable USP monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list. Substances placed in 'Category 2' are those the agency has identified as raising significant safety risks.
Beginning in 2022 and expanding through 2023, the FDA assigned several widely marketed peptides to Category 2. The practical effect was immediate: compounding pharmacies that had supplied wellness clinics stopped shipping those substances, and the supply chain shifted almost entirely toward vendors labeling products 'for research use only.'
That label is a legal fiction with real consequences. A research-use-only designation does not make a product legal for human administration; it means the seller is not claiming it is. Purity, sterility, and identity are unverified, and analytical surveys repeatedly find label deviations in grey-market vials.
For anyone tracking this space, the takeaway is that regulatory status in the US now splits sharply into two tiers: FDA-approved peptide drugs with prescription pathways, and everything else, where lawful human use effectively does not exist outside a registered clinical trial.